Quarterly report · Q2
3353.TEDINET S100PCTW
Period2022-03-01 → 2022-08-31
Filed2022-10-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥17.0bn | 2022-03-01 → 2022-08-31 | Cons. | Net sales |
| Revenue | ¥33.6bn | 2021-03-01 → 2022-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥16.8bn | 2021-03-01 → 2021-08-31 | Cons. | Net sales |
| Operating income | ¥466m | 2022-03-01 → 2022-08-31 | Cons. | Operating income |
| Operating income | ¥645m | 2021-03-01 → 2021-08-31 | Cons. | Operating income |
| Ordinary income | ¥598m | 2022-03-01 → 2022-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.4bn | 2021-03-01 → 2022-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥682m | 2021-03-01 → 2021-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥624m | 2022-03-01 → 2022-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥781m | 2021-03-01 → 2021-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥374m | 2022-03-01 → 2022-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥852m | 2021-03-01 → 2022-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥444m | 2021-03-01 → 2021-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥386m | 2022-03-01 → 2022-08-31 | Cons. | Profit loss |
| Net income | ¥452m | 2021-03-01 → 2021-08-31 | Cons. | Profit loss |
| Total assets | ¥28.3bn | at 2022-08-31 | Cons. | Assets |
| Total assets | ¥29.1bn | at 2022-02-28 | Cons. | Assets |
| Total assets | ¥30.2bn | at 2021-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥16.1bn | at 2022-08-31 | Cons. | Liabilities |
| Total liabilities | ¥17.2bn | at 2022-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥12.2bn | at 2022-08-31 | Cons. | Net assets |
| Net assets / equity | ¥11.9bn | at 2022-02-28 | Cons. | Net assets |
| Net assets / equity | ¥11.6bn | at 2021-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.0bn | at 2022-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥8.0bn | at 2022-02-28 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.8bn | at 2022-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.8bn | at 2022-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.4bn | at 2021-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.8bn | at 2021-02-28d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥496m | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2021-03-01 → 2022-02-28 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥334m | 2021-03-01 → 2021-08-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥291m | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥216m | 2021-03-01 → 2022-02-28 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥47m | 2021-03-01 → 2021-08-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.2bn | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥65m | 2021-03-01 → 2022-02-28 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.3bn | 2021-03-01 → 2021-08-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥99.65 | 2022-03-01 → 2022-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.26 | 2022-06-01 → 2022-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥226.92 | 2021-03-01 → 2022-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.22 | 2021-03-01 → 2021-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.13 | 2021-06-01 → 2021-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 41.2% | at 2022-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2022-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2021-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-08-31 | −¥497m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-08-31 | −¥497m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-08-31 | −¥385m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥11.6bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥11.6bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥736m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥35m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥1.9bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥1.4bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥495m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥20m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥95m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥94m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥876,000 |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥61m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-03-01 → 2022-08-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-03-01 → 2022-08-31 | ¥17.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥497m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-03-01 → 2022-08-31 | ¥851m |
| Reconciling Itemsreconciling | revenue | 2021-03-01 → 2021-08-31 | −¥545m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-03-01 → 2021-08-31 | −¥545m |
| Reconciling Itemsreconciling | segment profit | 2021-03-01 → 2021-08-31 | −¥347m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2021-03-01 → 2021-08-31 | ¥11.3bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2021-03-01 → 2021-08-31 | ¥11.3bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2021-03-01 → 2021-08-31 | ¥731m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2021-03-01 → 2021-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2021-03-01 → 2021-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2021-03-01 → 2021-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2021-03-01 → 2021-08-31 | ¥146m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2021-03-01 → 2021-08-31 | ¥2.0bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2021-03-01 → 2021-08-31 | ¥1.4bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2021-03-01 → 2021-08-31 | ¥543m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2021-03-01 → 2021-08-31 | ¥50m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2021-03-01 → 2021-08-31 | ¥117m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2021-03-01 → 2021-08-31 | ¥116m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2021-03-01 → 2021-08-31 | ¥960,000 |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2021-03-01 → 2021-08-31 | ¥65m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-03-01 → 2021-08-31 | ¥17.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-03-01 → 2021-08-31 | ¥16.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-03-01 → 2021-08-31 | ¥545m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-03-01 → 2021-08-31 | ¥992m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 501
| Item | Context | Value | Unit |
|---|---|---|---|
| Company name in english cover page | FilingDateInstant | Medical Ikkou Group Co.,Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 南野 利久 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)三重県津市西丸之内36番25号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)059－226－1193（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)上席執行役員 財務・ＩＲ部長 遠山 邦彦 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)三重県津市西丸之内36番25号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)059－226－1193（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)上席執行役員 財務・ＩＲ部長 遠山 邦彦 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E03443 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 33530 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社メディカル一光グループ | |
| Filer name in english | FilingDateInstant | Medical Ikkou Group Co.,Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-03-01 | |
| Current period end date | FilingDateInstant | 2022-08-31 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2023-02-28 | |
| Previous fiscal year start date | FilingDateInstant | 2021-03-01 | |
| Comparative period end date | FilingDateInstant | 2021-08-31 | |
| Previous fiscal year end date | FilingDateInstant | 2022-02-28 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所スタンダード市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式 100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |